Cover Image

MetrioPharm AG的產品平台分析

MetrioPharm AG - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 256139
出版日期 內容資訊 英文 21 Pages
Back to Top
MetrioPharm AG的產品平台分析 MetrioPharm AG - Product Pipeline Review - 2014
出版日期: 2014年09月15日 內容資訊: 英文 21 Pages



MetrioPharm AG,是在瑞士擁有總公司的生物醫藥品企業。正在開發低分子化合物的開發及最佳化,開發著針對發炎、感染疾病、自體免疫性疾病、癌症、老年癡呆症等疾病的醫藥品。

本報告提供MetrioPharm AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。


MetrioPharm AG的基本資料

  • MetrioPharm AG概要
  • 主要資訊
  • 企業資料

MetrioPharm AG:R&D概要

  • 主要的治療範圍

MetrioPharm AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

MetrioPharm AG:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

MetrioPharm AG:藥物簡介

  • MP-1000
  • MP-1031
  • MP-1032

MetrioPharm AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

MetrioPharm AG:最新的開發平台資訊

MetrioPharm AG:開發暫停中的計劃

MetrioPharm AG:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司



Product Code: GMDHC06381CDB


Global Markets Direct's, 'MetrioPharm AG - Product Pipeline Review - 2014', provides an overview of the MetrioPharm AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MetrioPharm AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of MetrioPharm AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of MetrioPharm AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the MetrioPharm AG's pipeline products

Reasons to buy

  • Evaluate MetrioPharm AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of MetrioPharm AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the MetrioPharm AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of MetrioPharm AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of MetrioPharm AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of MetrioPharm AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • MetrioPharm AG Snapshot
    • MetrioPharm AG Overview
    • Key Information
    • Key Facts
  • MetrioPharm AG - Research and Development Overview
    • Key Therapeutic Areas
  • MetrioPharm AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • MetrioPharm AG - Pipeline Products Glance
    • MetrioPharm AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • MetrioPharm AG - Drug Profiles
    • MP-1000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MP-1031
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MP-1032
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • MetrioPharm AG - Pipeline Analysis
    • MetrioPharm AG - Pipeline Products by Target
    • MetrioPharm AG - Pipeline Products by Route of Administration
    • MetrioPharm AG - Pipeline Products by Molecule Type
    • MetrioPharm AG - Pipeline Products by Mechanism of Action
  • MetrioPharm AG - Recent Pipeline Updates
  • MetrioPharm AG - Dormant Projects
  • MetrioPharm AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • MetrioPharm AG, Key Information
  • MetrioPharm AG, Key Facts
  • MetrioPharm AG - Pipeline by Indication, 2014
  • MetrioPharm AG - Pipeline by Stage of Development, 2014
  • MetrioPharm AG - Monotherapy Products in Pipeline, 2014
  • MetrioPharm AG - Preclinical, 2014
  • MetrioPharm AG - Pipeline by Target, 2014
  • MetrioPharm AG - Pipeline by Route of Administration, 2014
  • MetrioPharm AG - Pipeline by Molecule Type, 2014
  • MetrioPharm AG - Pipeline Products by Mechanism of Action, 2014
  • MetrioPharm AG - Recent Pipeline Updates, 2014
  • MetrioPharm AG - Dormant Developmental Projects,2014
  • MetrioPharm AG, Other Locations

List of Figures

  • MetrioPharm AG - Pipeline by Top 10 Indication, 2014
  • MetrioPharm AG - Pipeline by Top 10 Target, 2014
  • MetrioPharm AG - Pipeline by Top 10 Route of Administration, 2014
  • MetrioPharm AG - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top